Isotope Effect: A New Approach to Combating Neurological and Mitochondrial Diseases.
A presentation at the Moscow State University by CSO Dr. Misha Shchepinov regarding the mechanism of action of Retrotope’s RT001, and its effectiveness in a variety of disease models.
February 16, 2021
Anil Kumar, Retrotope’s president and chief business officer, gave a corporate presentation as part of the 2021 BIO CEO & Investor Digital Conference. The presentation highlighted a busy year ahead for Retrotope with multiple key data readouts planned for its broad clinical-stage pipeline.
February 1, 2021
A matchstick animation illustrating the concept of the LPO in lipid membranes, and the role of D-PUFAs in inhibiting the chain reaction.
April 21, 2020
Dr. Mark Midei, Retrotope's Chief of Medical Affairs, and Susan Walther, Director of Patient Engagement at Friedreich's Ataxia Research Alliance (FARA), recorded a video about Retrotope’s Friedreich’s ataxia study.
May 17, 2019
Dr. Charles Cantor, co-founder and executive director of Retrotope, Inc., presenting on GoldLab Symposium 2019.
March 31, 2019
Mikhail Shchepinov, Chief Scientific Officer at Retrotope, Inc., presenting at Undoing Aging 2019 in Berlin.
October 18, 2018
Retrotope released new data at the National Organization of Rare Diseases’ Rare Diseases & Orphan Products Breakthrough Summit (NORD Summit) regarding the impact of RT001 on disease progression in 2 patients with infantile neuroaxonal dystrophy (INAD). Dr. Mark Midei discusses what makes RT001 unique.
April 2, 2017
In this 18 minute presentation, Dr. Harry J. Saal, Retrotope’s Chairman, explains to a TEDx audience how Retrotope’s technology impacts the membranes that are frequently damaged in many neurological diseases.
October 12, 2015
A presentation at the University of Pennsylvania by Dr. Harry J. Saal, regarding how Retrotope's RT001 addresses the orphan disease Friedreich's ataxia.